Tag Archive for: biotech

Ariceum Therapeutics Expands Pipeline with Acquisition of Theragnostics Ltd

/in

Acquisition of next generation radiopharmaceutical clinical pipeline to include Auger-based systemic targeted PARP inhibitor radiation therapies Expansion of operations in the US Acquisition of commercial FDA-approved, diagnostic product NEPHROSCANTM in partnership with GE Healthcare and Ga-68 kit technology IP currently licensed to Novartis Theragnostics’ and Ariceum’s leadership teams to join forces creating a specialist team of […]

Read more

Scarlet Therapeutics: A Bright Spot in Bristol’s Biotech Scene

/in

Scarlet Therapeutics, a leader in red blood cell-based therapeutics (tRBCs), has launched with seed funding from Science Creates Ventures and Meltwind to further develop its platform.  Born out of more than a decade of research at the University of Bristol and spearheaded by Professors Ashley Toye and Jan Frayne, with CEO Alistair Irvine at the […]

Read more

Adcendo ApS Announces Option License Agreement with Duality Biologics to Enhance Optionality to Further Expand First-in-class ADC Pipeline

/in

Strengthening of strategic option license agreement to cover additional novel ADC targets Copenhagen, Denmark, May 30th, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need, announced the expansion of its current collaboration with Duality Biologics (“Duality”), a clinical-stage […]

Read more

Engimmune Therapeutics Announces the Appointment of Dr Annalisa D’Andrea to its Board of Directors

/in

Leading industry expert with more than 25 years of experience in translation research in immunology  Basel, Switzerland, 23 May 2023. Engimmune Therapeutics AG (“Engimmune”), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, is pleased to announce the appointment of Dr Annalisa D’Andrea to its board of directors as a non-executive director as of […]

Read more

Peer-Reviewed Translational Research Paves The Way For First-In-Class Autotaxin Inhibitor IOA-289 In Cancer

/in

Amsterdam, The Netherlands and Geneva, Switzerland, 16 May 2023 – iOnctura, a clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer, today announces the peer-reviewed publication of comprehensive translational research on the novel autotaxin (ATX) inhibitor IOA-289 in the ESMO journal Immuno-Oncology and Technology (IOTECH). Read more…

Read more
© Optimum Strategic Communications.